Predictive Measures to Stratify Clinical Outcomes in Children and Adults With Gaucher Disease and Responses to Specific Therapies

Status: Recruiting
Location: See all (8) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

The purpose of this research is to review data already collected and to collect new data from adults and children in England with Gaucher Disease to determine clinical factors which predict severity and response to therapy of Gaucher disease especially in the areas of bone, cancer and brain conditions.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

⁃ Each patient must meet all of the following criteria to be enrolled in this study:

• Confirmed biochemical diagnosis of Type I, Type II or Type III Gaucher disease

• Written Ethics Committee (EC) approved informed consent obtained from the patient, or patient's parent or legal guardian and patient assent if appropriate

• Male or Female patients, no age limitation

• Willing and able to comply with study schedule and procedures

• Deceased patients for whom the EC determines that patient data can be collected without a new consent from the patient

Locations
Other Locations
United Kingdom
Birmingham Childrens Hospital
TERMINATED
Birmingham
New Queen Elizabeth Hospital
RECRUITING
Birmingham
Cambridge University Hospital
RECRUITING
Cambridge
Great Ormond Street Hospital
RECRUITING
London
National Hospital for Neurology and Neurosurgery
RECRUITING
London
Royal Free Hospital
RECRUITING
London
Royal Manchester Childrens Hospital
RECRUITING
Manchester
Salford Royal NHS Foundation Trust
RECRUITING
Salford
Contact Information
Primary
Elizabeth M MORRIS, RN
liz.morris@addenbrookes.nhs.uk
+441223274634
Backup
Chong Y TAN, MB PhD
chongyew.tan@addenbrookes.nhs.uk
+441223274634
Time Frame
Start Date: 2014-01-01
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 250
Treatments
Patients Type III
Stratified response to EnzymeTherapy Substrate Reduction Therapy (expected) Splenectomy (and interactions)
Patients Type I
Stratified response to Enzyme Therapy and Substrate Reduction Therapy- Splenectomy (and interactions)
Related Therapeutic Areas
Sponsors
Collaborators: Medical Research Council, National Institute for Health Research, United Kingdom
Leads: Cambridge University Hospitals NHS Foundation Trust

This content was sourced from clinicaltrials.gov